Sign In
Buy JAZZ
$252.86
-5.52 (-2.14%)
At Close: Jul 31, 2026
Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term
10:50am, Monday, 24'th Mar 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
5 High ROE Stocks to Buy as Markets Dip Despite Rate Cut Hopes
01:05pm, Friday, 21'st Mar 2025
MPLX, LDOS, JAZZ, FTNT and PPC are some of the stocks with high ROE to profit from as markets falter on tariff concerns.
4 Top PEG Stocks Based on GARP Approach to Smart Investing
10:41am, Thursday, 20'th Mar 2025
Here are four discounted PEG stocks, JAZZ, FMS, DAN and ITRI, which qualify our screening criteria.
Does Jazz (JAZZ) Have the Potential to Rally 38.94% as Wall Street Analysts Expect?
10:55am, Wednesday, 19'th Mar 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 38.9% in Jazz (JAZZ). While the effectiveness of this highly sought-after metric is questionable, the positive
Updated top-line results demonstrate improved outcomes in adults with narcolepsy or idiopathic hypersomnia treated with Xywav as observed in the Phase 4 DUET (Developing Understanding of Hypersomnia
JAZZ or ILMN: Which Is the Better Value Stock Right Now?
12:41pm, Friday, 14'th Mar 2025
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Illumina (ILMN). But which of these two stocks is more attractive to value inv
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
10:45am, Friday, 14'th Mar 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Follow the Leader: 2 Biopharma Stocks Showing Relative Strength in 2025
01:12pm, Thursday, 13'th Mar 2025
Despite a correction to begin the year, there are a few pockets of the market that are working.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of C
4 Discounted PEG Stocks Offering the Best Returns to Value Investors
09:46am, Monday, 10'th Mar 2025
Here we present four discounted PEG stocks that qualify our screening criteria, TAP, BMRN, DVN and JAZZ.
The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals
04:01am, Friday, 07'th Mar 2025
Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals are included in this Analyst Blog.
Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio
10:10am, Thursday, 06'th Mar 2025
JAZZ's acquisition of CMRX is set to add a rare high-grade brain tumor drug currently under the FDA's review. The deal is likely to be closed by June 2024.
Beat Market Volatility With 4 Low-Beta Stocks: PGR, PSO, TXO & JAZZ
09:05am, Thursday, 06'th Mar 2025
It is imperative to build a portfolio of low-beta stocks to navigate a volatile market. PGR, PSO, TXO & JAZZ are well-poised to gain.
3 Highly Ranked Medical Stocks to Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX,
04:10pm, Wednesday, 05'th Mar 2025
These highly ranked medical stocks have the value and essential services that investors may be looking for as tariff concerns and geopolitical tensions have started to rattle markets.
Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline
08:41am, Wednesday, 05'th Mar 2025
On Tuesday, Jazz Pharmaceuticals plc JAZZ agreed to acquire Chimerix Inc CMRX for $8.55 per share in cash, representing a total consideration of approximately $935 million.
